- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05709353
MDMA-assisted Prolonged Exposure Therapy for Comorbid Alcohol Use Disorder and Post-traumatic Stress Disorder (MPATHY)
A Randomised, Controlled Trial of MDMA-assisted Prolonged Exposure Therapy for Comorbid Alcohol Use Disorder and Post-traumatic Stress Disorder
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
New strategies for the treatment of comorbid PTSD and alcohol dependence are urgently required. Recent evidence has shown strong support for trauma-focused integrated treatments (namely COPE), however, only 49% demonstrate clinically significant improvements. MDMA may be a promising approach to improve response to COPE for this population. Emerging evidence suggests that MDMA-assisted therapy may be of promise for PTSD, and has demonstrated a good safety profile and potential efficacy in alcohol dependence.
This project will evaluate the clinical efficacy and tolerability of MDMA-assisted COPE relative to a control-assisted COPE. Active control used in this study is niacin. The investigators hypothesise that MDMA treated participants will be have a reduction in PTSD symptom severity as well as heavy drinking.
The trial will utilise a double blind, randomised, controlled design. A sample of 120 individuals will receive 14 weeks of treatment including 12 COPE sessions and 2 dosing sessions with MDMA (80-160mg) or control (niacin 250mg).
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Kirsten C Morley, PhD
- Phone Number: 61295153636
- Email: Kirsten.morley@sydney.edu.au
Study Contact Backup
- Name: Ellen Towers
- Email: ellen.towers@sydney.edu.au
Study Locations
-
-
New South Wales
-
Sydney, New South Wales, Australia, 2050
- Recruiting
- Drug Health Services, Royal Prince Alfred Hospital
-
Contact:
- Paul Haber, MBBS
- Email: paul.haber@sydney.edu.au
-
-
Victoria
-
Richmond, Victoria, Australia, 3121
- Not yet recruiting
- Turning Point
-
Contact:
- Shalini Arunogiri, MBBS
- Email: shaliniA@turningpoint.org.au
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Both AUD and current PTSD according to the DSM-5 criteria, for 6 months or longer with at least moderate severity, according to investigator judgement and CAPS-5
- Aged ≥18 years old
- Adequate cognition and English language skills to give valid consent and complete research interviews assessments
- Willing to give written informed consent
- Received prior treatment for PTSD or AUD (not including study interventions)
- Stable housing
- Able to identify a significant other (such as a family/friend/partner) who could accompany them from clinic/provide transport and/or be contacted by the study team if required
Exclusion Criteria:
History of, or currently meeting, DSM-5 criteria for:
- current or lifetime psychotic or bipolar disorders, or
- major depression with psychotic features Assessed via Structured Clinical Interview for DSM-5 - Research Version (SCID-5-RV). Potential participants will be screened for personality disorders but suitability will then be confirmed by clinical interview given the prevalence of high scores in this comorbid population
- Pregnant or lactating (contraception must be used and a sensitive pregnancy test will be performed at baseline and prior to dosing)
- Significant alcohol withdrawal (current Clinical Institute Withdrawal Assessment for Alcohol [CIWA-Ar] score ≥10, including history of delirium tremens or alcohol withdrawal seizures).
- Concurrent use of psychotropic medication (antidepressants and alcohol pharmacotherapy use considered if assessed by physician and titrated down with 5 half-lives + 1 week washout)
- Use of, and unable or unwilling to cease, any medications likely to interact with MDMA in the opinion of the physicians and investigators during the trial (low dose opiates are permitted for pain management but not the night before or after MDMA sessions)
- Substance use disorder other than tobacco (e.g. benzodiazepines, cannabis)
- Abnormal clinical findings including a history of, or current: cardiac disease and/or dysrhythmia, uncontrolled hypertension or severe hypotension, abnormal electrocardiogram findings, stroke, liver disease, a history of epilepsy, hyponatraemia, or malignant hyperthermia (controlled hypertension and diabetes type II may be permitted)
Suicide risk according to clinician judgement and responses to Columbia Suicide Severity Rating Scale-Lifetime (C-SSRS-L) and SCID-5-RV.
• Details surrounding any previous attempts >6 months ago will be gathered whereby attempts related to their trauma/PTSD and/or associated with the use of psychostimulants will contribute to risk assessment and guide trial safety measures if enrolled
- Clinically unstable systemic medical (e.g., cancer) or psychiatric disorder or condition that might require hospitalisation that precludes trial participation
- Regular use of ecstasy (e.g. at least twice in last 6 months, or >10 times within the last 5 years)
- Enrolled in any other interventional clinical trials in the previous two months or over the duration of the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: COPE + MDMA
4x COPE sessions Dose 1: 2x MDMA capsules (80mg) + 1x niacin-matched placebo capsule Optional supplementary dispense: 1x MDMA capsule (40mg) 4x COPE sessions Dose 2: 2x MDMA capsules (80mg) + 1x niacin-matched placebo capsule Optional supplementary dispense: 1x OR 2x white MDMA capsule (40 or 80mg) 4x COPE sessions |
COPE represents an integration of existing evidence-based manualised CBT interventions for PTSD and substance dependence (see manual DOI: 10.1093/med:psych/9780199334513.001.0001). COPE used in the current study will represent an integration of existing evidence-based manualised CBT interventions for PTSD and substance dependence. COPE only begins when the participant in a safe environment and no longer in contact with the traumatic event/exposure. COPE employs imaginal and in vivo exposures to treat PTSD and consists of 12 individual 90-minute sessions (i.e. 19.5 hours) delivered by a clinical psychologist.
Other Names:
Administration of 80 to 160 mg MDMA across two 'dosing' sessions.
Supplemental doses (additional 40mg during first session, additional 40- 80mg during second session) will be dependent on clinician and participant consensus during preparatory period of 'dosing session'.
These supplemental amounts will be dispensed 60 to 90 minutes after initial 80 mg dose.
Other Names:
|
Other: COPE + Niacin (Control)
4x COPE sessions Dose 1: 2x MDMA-matched placebo capsules + 1x niacin capsule (250mg) Optional supplementary dispense: 1x MDMA-matched placebo capsule 4x COPE sessions Dose 2: 2x MDMA-matched placebo capsules + 1x niacin capsule (250mg) Optional supplementary dispense: 1x OR 2x MDMA-matched placebo capsule 4x COPE sessions |
COPE represents an integration of existing evidence-based manualised CBT interventions for PTSD and substance dependence (see manual DOI: 10.1093/med:psych/9780199334513.001.0001). COPE used in the current study will represent an integration of existing evidence-based manualised CBT interventions for PTSD and substance dependence. COPE only begins when the participant in a safe environment and no longer in contact with the traumatic event/exposure. COPE employs imaginal and in vivo exposures to treat PTSD and consists of 12 individual 90-minute sessions (i.e. 19.5 hours) delivered by a clinical psychologist.
Other Names:
Administration of niacin 250mg or niacin-matched placebo during two 'dosing' sessions.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
change in clinician-rated PTSD severity via Clinician-Administered PTSD Scale for DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition) (CAPS-5) from baseline to visit 16.
Time Frame: 52 weeks
|
CAPS-5 is a structured diagnostic interview with excellent psychometric properties and diagnostic efficiency and used widely in MDMA-assisted PTSD studies. The CAPS-5 will be administered by independent evaluators blind to treatment condition. CAPS-5 total symptom severity score is calculated by summing severity scores for the 20 DSM-5 PTSD symptoms. CAPS-5 symptom cluster severity scores are calculated by summing the individual item severity scores for symptoms corresponding to a given DSM-5 cluster: Criterion B (items 1-5); Criterion C (items 6-7); Criterion D (items 8-14); and, Criterion E (items 15-20). |
52 weeks
|
change in self-reported PTSD symptom severity via Post-Traumatic Stress Disorder Checklist for DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition) (PCL-5) from baseline to visit 16.
Time Frame: 52 weeks
|
PCL-5 has excellent psychometric characteristics for a secondary indicator of PTSD symptom severity. Items are summed to provide a total severity score (range = 0-80). The PCL-5 can determine a provisional diagnosis in two ways: Summing all 20 items (range 0-80) and using a cut-point score of 31-33 appears to be reasonable based upon current psychometric work. |
52 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Heavy Drinking Days per week (HDDs) (>5 standard drinks/day for men; >4 for women)
Time Frame: 52 weeks
|
This will be measured by the Timeline Follow Back and corroborated with Phosphatidylethanol (PEth) levels
|
52 weeks
|
Absence of any HDD
Time Frame: 52 weeks
|
Measured by Timeline Follow Back and corroborated with Phosphatidylethanol (PEth) levels
|
52 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean alcohol consumption per drinking day
Time Frame: 52 weeks
|
Measured by Timeline Follow Back and corroborated with Phosphatidylethanol (PEth) levels
|
52 weeks
|
Change in dependence Severity
Time Frame: 52 weeks
|
Measured by the Alcohol Dependence Scale.
The minimum score is 0 and the maximum score is 47.
A higher score indicates more severe dependence.
|
52 weeks
|
Changes in Anxiety
Time Frame: 52 weeks
|
Measured by cumulative scores on the DASS-21 Anxiety Scale.
This scale has a minimum score of 0 and maximum score of 21.
A higher score indicates more anxiety.
|
52 weeks
|
Changes in Depression
Time Frame: 52 weeks
|
Measured by cumulative scores on the DASS-21 Depression Scale.
This scale has a minimum score of 0 and maximum score of 21.
A higher score indicates greater depression.
|
52 weeks
|
Changes in Stress
Time Frame: 52 weeks
|
Measured by cumulative scores on the DASS-21 Stress Scale.
This scale has a minimum score of 0 and maximum score of 21.
A higher score indicates more stress.
|
52 weeks
|
Sleep Disturbances
Time Frame: 52 weeks
|
As measured by the ISI (Insomnia Severity Index).
This Index has a minimum score of 0 and a maximum score of 28.
The higher the score indicates more severe insomnia.
|
52 weeks
|
Changes in Suicidal Ideation
Time Frame: 52 weeks
|
Changes in suicidal ideation & behaviours across the treatment period.
This will be measured on the C-SRSS (Columbia Suicide Severity Rating Scale).
At baseline this will be measured by the baseline version.
At each visit following this, this will be recorded on the since last visit version.
Higher scores indicate more severe suicidality.
|
52 weeks
|
Changes PTSD cognitions
Time Frame: 52 weeks
|
As measured by the PTCI.
This is a 33 question inventory measures negative cognitions about the self & world, as well as self-blame.
Higher scores indicate more negative cognitions.
|
52 weeks
|
Drinking Diary
Time Frame: 16 weeks
|
Daily texts will be sent out to participants querying the amount of alcohol they have consumed.
Participant responses to this will be recorded.
This will be managed through SEMA software.
|
16 weeks
|
Mood states
Time Frame: 16 weeks
|
Daily texts will be sent out to participants querying their moods.
This will be in line with the POMS instrument (Profile of Mood States).
|
16 weeks
|
Mood following dosing session
Time Frame: week 5, week 10
|
The week following each dosing session will involve calls with participants to complete POMS (profile of mood states)
|
week 5, week 10
|
Changes in Quality of Life
Time Frame: 16 weeks
|
To assess whether treatment can change quality of life as measured by the short form Health Survey (SF-36).
This survey has 36 items that measure 8 domains of health, including: physical functioning, physical role limitations, bodily pain, general health perceptions, energy/vitality, social functioning, emotional role limitations and mental health.
The scores are transformed to range from 0 (worst possible health) to 100 (best possible health).
|
16 weeks
|
Changes in use of Health Services
Time Frame: 16 weeks
|
As measured by the Brief Health Services Use Questionnaire.
This questionnaire assesses Health Service Use across the last 3 months.
It is a qualitative questionnaire.
|
16 weeks
|
Therapeutic Alliance between therapist
Time Frame: 16 weeks
|
As measured by the Helping Alliance Questionnaire (HAQ-II).
This instrument will be completed by the patient (patient version) and the clinician (clinician version).
This outlines how a person may feel or behave in relation to their therapist.
Higher scores indicates a better therapeutic alliance.
|
16 weeks
|
COPE Session Rating Scale
Time Frame: 16 weeks
|
As measured by the session rating scale (SRS).
Following each COPE session, both the therapist and participant will complete a brief post-session rating.
This scale measures; relationship, goals & topics, approach or method and overall psychotherapy session.
Higher scores on each of these indicate a more positive experience.
|
16 weeks
|
Treatment Satisfaction as measured by the YES (your experience of service).
Time Frame: 16 weeks
|
This instrument is designed to gather information from consumers about their experiences of care.
|
16 weeks
|
Treatment Satisfaction ss measured by the CSQ-8 (client satisfaction questionnaire).
Time Frame: 16 weeks
|
This instrument measures clients satisfaction with treatment.
Total scores range from 8 to 32, with the higher number indicating greater satisfaction.
|
16 weeks
|
Measurement of Distress ss measured by a Likert Scale
Time Frame: week 5, week 12
|
This instrument will be administered hourly within the dosing sessions.
It aims to measure the participant's mood on a scale of 1 (worst) -10 (best)
|
week 5, week 12
|
Measurement of Drug Effect as measured by the Revised Mystical Experience Questionnaire 30 (MEQ-30)
Time Frame: week 5, week 12
|
MEQ-30 Measures mystical, positive mood, transcendence, ineffability experienced in dosing sessions. MEQ-30 will be compelted at the end of each dosing session. participants will be asked to rate rate the degree to which at any time during that session they experienced certain phenomena on a scale of 0 (not at all) to 5 (more than any other time in their life) |
week 5, week 12
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Kirsten C Morley, PhD, University of Sydney
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Chemically-Induced Disorders
- Drinking Behavior
- Alcohol-Related Disorders
- Substance-Related Disorders
- Trauma and Stressor Related Disorders
- Alcohol Drinking
- Alcoholism
- Stress Disorders, Traumatic
- Stress Disorders, Post-Traumatic
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Vasodilator Agents
- Autonomic Agents
- Peripheral Nervous System Agents
- Antimetabolites
- Micronutrients
- Hypolipidemic Agents
- Lipid Regulating Agents
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Dopamine Agents
- Vitamins
- Dopamine Uptake Inhibitors
- Vitamin B Complex
- Central Nervous System Stimulants
- Sympathomimetics
- Adrenergic Uptake Inhibitors
- Methamphetamine
- Niacin
Other Study ID Numbers
- X22-0121
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alcohol Dependence
-
University Hospital, LilleCompleted
-
Tel-Aviv Sourasky Medical CenterMinistry of Health, IsraelUnknownAlcohol-dependenceIsrael
-
Pop Test Oncology LLCBaylor College of Medicine; Michael E. DeBakey VA Medical Center; Congressionally... and other collaboratorsCompletedPotential Treatment for Alcohol Dependence-Alcohol InteractionUnited States
-
DynamiCare HealthNational Institute on Alcohol Abuse and Alcoholism (NIAAA); RANDActive, not recruitingAlcohol Dependence | Alcohol Use Disorder | Drug DependenceUnited States
-
National Institute on Alcohol Abuse and Alcoholism...CompletedAlcohol Abuse | Alcohol Dependence (Primary Condition)United States
-
University Hospital, Gentofte, CopenhagenCompleted
-
Massachusetts General HospitalCompletedAlcohol Dependence | Drug Abuse | Alcohol Abuse | Drug DependenceUnited States
-
Psychiatric Centre RigshospitaletThe Novavì outpatient clinics, CopenhagenRecruitingAddiction, Alcohol | Alcohol Dependence, in RemissionDenmark
-
University of WashingtonU.S. Army Medical Research and Development CommandCompletedAlcohol Dependence | Substance Abuse | Alcohol Abuse | Substance DependenceUnited States
-
Anders Fink-Jensen, MD, DMSciThe Novavì outpatient clinics, Copenhagen; Neurobiology Research Unit, Rigshospitalet... and other collaboratorsCompletedAddiction, Alcohol | Alcohol Dependence, in RemissionDenmark
Clinical Trials on Prolonged exposure therapy
-
University of PennsylvaniaMedical University of South Carolina; U.S. Army Medical Research and Development...CompletedPosttraumatic Stress Disorder | Combat DisorderUnited States
-
Emory UniversityCenters for Disease Control and PreventionWithdrawnPost Traumatic Stress Disorder, PTSD
-
Baylor Research InstituteActive, not recruitingSpinal Cord Injuries | Posttraumatic Stress DisorderUnited States
-
Veterans Medical Research FoundationUniversity of Pennsylvania; United States Department of DefenseCompletedDepression | Posttraumatic Stress Disorders | AnxietyUnited States
-
Veterans Medical Research FoundationUniversity of Minnesota; Center for Veterans Research and EducationNot yet recruitingStress Disorders, Post-Traumatic | Substance Use DisordersUnited States
-
University of PennsylvaniaCompletedPTSD | Posttraumatic Stress DisorderUnited States
-
Chang Gung UniversityMinistry of Science and Technology, TaiwanUnknownPosttraumatic Stress DisorderTaiwan
-
Rabin Medical CenterUnknownPTSD | Traumatic Brain Injury | Post Concussive SyndromeIsrael
-
University of PennsylvaniaNational Institute of Mental Health (NIMH)CompletedPost-Traumatic Stress DisorderUnited States
-
Kent State UniversityNational Institute of Mental Health (NIMH); Summa Health SystemUnknownHIV Infections | Stress Disorders, Post-TraumaticUnited States